Katarzyna Przewłócka

Katarzyna Przewłócka

Auto-generated profile, based on publicly available information

Katarzyna Przewłócka

Department of Bioenergetics and Physiology of Exercise, Medical University of Gdansk, 80-210 Gdansk, Poland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Karolina Kaźmierczak-SiedleckaKarolina Kaźmierczak-Siedlecka
Karolina Kaźmierczak-Siedlecka
ADAleš Dvořák
Aleš Dvořák
MFMarcin Folwarski
Marcin Folwarski
ADAgnieszka Daca
Agnieszka Daca
KPKatarzyna Przewłócka
Katarzyna Przewłócka
WMWojciech Makarewicz
Wojciech Makarewicz
The association between bacterial as well as viral gut microbiota imbalance and carcinogenesis has been intensively analysed in many studies; nevertheless, the role of fungal gut microbiota (mycobiota) in colorectal, oral, and pancreatic cancer development is relatively new and undiscovered field due to low abundance of intestinal fungi as well as lack of well-characterized reference genomes. Several specific fungi amounts are increased in colorectal cancer patients; moreover, it was observed that the disease stage is strongly related to the fungal microbiota profile; thus, it may be used as a potential diagnostic biomarker for adenomas. Candida albicans, which is the major microbe contributing to oral cancer development, may promote carcinogenesis via several mechanisms, mainly triggering inflammation. Early detection of pancreatic cancer provides the opportunity to improve survival rate, therefore, there is a need to conduct further studies regarding the role of fungal microbiota as a potential prognostic tool to diagnose this cancer at early stage. Additionally, growing attention towards the characterization of mycobiota may contribute to improve the efficiency of therapeutic methods used to alter the composition and activity of gut microbiota. The administration of Saccharomyces boulardii in oncology, mainly in immunocompromised and/or critically ill patients, is still controversial.